Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, February 05, 2020
X-Chem announced a drug discovery partnership with ALK, a Danish pharmaceutical company focused on the prevention and treatment of allergies.
read more
Alkermes has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center for ALKS 4230, Alkermes' immuno-oncology drug candidate.
read more
Tuesday, January 07, 2014
Alkermes plc (NASDAQ:ALKS) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 14/032,736, entitled “Prodrugs of fumarates and their use in treating various diseases....
read more
Alkermes plc (NASDAQ: ALKS) today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four of Alkermes’ pipeline candidates for the treatment of central nervous system (CNS) disorders: aripiprazole...
read more
Wednesday, April 17, 2013
Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for ...
read more
Alkermes announced the appointment of James Robinson as President and Chief Operating Officer, effective March 5, 2018.
read more
Alkermes plc today announced that it has expanded its senior management team by appointing two industry veterans to newly created roles. Srdjan (Serge) Stankovic, M.D., MSPH, will serve as Senior Vice President of Clinical Development and Medical ...
read more
Tuesday, November 12, 2019
Alkermes announced the receipt of a $150 million milestone payment from Biogen triggered by the recent FDA approval of VUMERITY.
read more
Alkermes plc today will present an overview of its proprietary pipeline portfolio at its Research and Development (R&D) Day meeting for analysts and investors. For the first time, the company will discuss three new drug candidates including: a ...
read more
Saturday, September 25, 2021
Allarity Therapeutics A/S, a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers, and Lonza, a CDMO partner to the biopharma industry, announced an ...
read more
Thursday, February 23, 2023
AllCells®, a Discovery Life Sciences™ company announced the expansion of its apheresis network with the addition of two new centers in Houston, Texas, and Huntsville, Alabama. These new centers complement AllCells' existing presence in two major U.S....
read more
Tuesday, October 06, 2015
Allele Biotechnology & Pharmaceuticals, a company involved in the development of specialized cells for regenerative medicine and pharmaceutical drug discovery, has announced plans to form a commercial business for the banking of human induced ...
read more
Allele Biotechnology & Pharmaceuticals has received a Tissue Bank License from the California Department of Public Health.
read more
Aptinyx announced Allergan has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator.
read more
Allergan is buying Kythera Biopharmaceuticals for about $2.1 billion, adding a drug that destroys fat cells and eliminates the cosmetic condition referred to as "double chin".
read more